November 16, 2026 1:31 PM 2 min read
Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
by Vandana Singh Benzinga Staff Writer
Follow
LXEOLexeo Therapeutics Inc
$3.087.14%
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
Reveal Full Score Edge Rankings
MomentumN/A
GrowthN/A
QualityN/A
ValueN/A
Price Trend
ShortMediumLongOverview Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) and outlined plans to launch a pivotal study in late 2027.
PKP2-ACM is an inherited heart muscle condition caused by a change, or variant, in the PKP2 gene.
The clinical-stage genetic medicine company dosed 10 participants, including three in Cohort 1 at a low dose (2×10^13 vg/kg) and seven in Cohorts 2 and 3 at a high dose (6×10^13 vg/kg).
By the October 15, 2026, data cutoff, nine…